EGFR and non-small cell lung carcinoma: Importantly, in a randomized trial comparing Osimertinib to first generation EGFR TKIs (erlotinib or gefitinib) in previously untreated NSCLC patients with EGFR-mutant tumors, osimertinib administration was associated with a significant improvement of PFS (17 vs. 8 months) and a trend towards an improved survival (after 18 months, 83% in the osimertinib arm, compared to 71% in standard EGF-TKIs arm) [330].